Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
AZELASTIN FLUTICASON Mepha 0.14/0.05mg 23 ml
Drug
Azelastin-Fluticason-Mepha, Nasenspray, Suspension
Symptomatische Behandlung der saisonalen allergischen Rhinitis und Rhinokonjunktivitis.
12.02.2. – combined vasoconstrictors / combined antihistamines / other combinations
HAM – Human medicine
NASSS – nasal spray, suspension
S – synthetic products for human use
B – Dispensed on prescription by a physician or veterinarian (B)
Z – approved
5/11/2023
5/10/2028
Dosage strength
Azelastin-Fluticason-Mepha, Nasenspray, Suspension
Symptomatische Behandlung der saisonalen allergischen Rhinitis und Rhinokonjunktivitis.
01
Z – approved
Package
7680687300018
In trade from / since 5/11/2023
A/R – Authorised / referenced
23 ml
001
Z – approved
Declaration
Component
0.137 mg azelastini hydrochloridum
0.05 mg fluticasoni propionas
0.05 mg fluticasoni propionas
cellulosum microcristallinum et carmellosum natricum
glycerolum
polysorbatum 80
dinatrii edetas
alcohol phenylethylicus
0.014 mg benzalkonii chloridum
aqua purificata
glycerolum
polysorbatum 80
dinatrii edetas
alcohol phenylethylicus
0.014 mg benzalkonii chloridum
aqua purificata
Spezialitätenliste***
SL
-
-
31.20
None
No
10%
Yes
Authorisation holder
7601001396685
Mepha Pharma AG
Kirschgartenstrasse 14
4051 Basel (BS)
Kirschgartenstrasse 14
4051 Basel (BS)
Date of revision of the text
4/29/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.